From September 1, 2026 to September 30, 2026, the Company conducted treasury stock acquisitions of its common stock through market purchases. The number of shares acquired was 106,400 shares, and the total acquisition amount was 426,244,500 yen. Acquisitions were made via listed market purchases; cumulative totals to date are 181,900 shares and 730,038,500 yen (as of September 30).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4547","jir_company_name":"Kissei Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4547-20261005-01.pdf","jir_short_summary":"From September 1, 2026 to September 30, 2026, the Company conducted treasury stock acquisitions of its common stock through market purchases. The number of shares acquired was 106,400 shares, and the total acquisition amount was 426,244,500 yen. Acquisitions were made via listed market purchases; cumulative totals to date are 181,900 shares and 730,038,500 yen (as of September 30).","jir_summary":"### Overview of Treasury Stock Acquisition\nAs treasury stock acquisitions under the Companies Act, the Company acquired its common stock through market purchases from September 1, 2026 to September 30, 2026. The total number of shares acquired was 106,400 shares, and the total acquisition amount was 426,244,500 yen. The acquisition method was market purchases (including discretionary market purchase agreements that include ToSTNeT-3), conducted through listed markets.\n\n### Cumulative Acquisition Status and Future Outlook\nBased on the board resolution on May 11, 2026, the cap was set at 1,300,000 shares (3.14% of the total outstanding shares) and a maximum amount of 6,000,000,000 yen; cumulative acquisitions to date have reached 181,900 shares and a cumulative acquisition amount of 730,038,500 yen. The Company may continue market purchases within the determined period for additional acquisitions.","jir_financial_highlights":"Type of Shares to be Acquired: Company common stock (Unknown)\nTotal Number of Shares Acquired: 106,400 shares (Unknown)\nTotal Acquisition Amount: 426,244,500 yen (Unknown)\nAcquisition Period: September 1, 2026\uff5eSeptember 30, 2026 (Unknown)\nAcquisition Method: Market purchases (Unknown)\nCumulative Shares Acquired (as of 2026\/9\/30): 181,900 shares (Unknown)\nCumulative Acquisition Amount (as of 2026\/9\/30): 730,038,500 yen (Unknown)","jir_category":"","jir_hashtags":"#KisseiPharmaceutical, #ShareBuyback","jir_key_figures":"106,400 shares: Number of shares acquired\n426,244,500 yen: Total acquisition amount\n181,900 shares: Cumulative shares acquired (as of 9\/30)","jir_meta_title":"Kissei Pharmaceutical Co., Ltd. \u2014 Notice of Treasury Stock Acquisition Status | September 2026 Results","jir_meta_description":"Kissei Pharmaceutical Co., Ltd. discloses treasury stock acquisition details for the period September 1\u201330, 2026: 106,400 shares acquired for a total of 426,244,500 yen. Cumulative total: 181,900 shares, 730,038,500 yen. Acquisitions conducted via market purchases.","jir_og_title":"Kissei Pharmaceutical Co., Ltd. Discloses Treasury Stock Acquisition Status","jir_og_description":"During the period, the Company acquired 106,400 shares for a total of 426,244,500 yen. Cumulative totals are 181,900 shares and 730,038,500 yen. Acquisitions were made via market purchases.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":8930,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_buyback","footnotes":""},"sector":[],"importance":[],"class_list":["post-127449","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n